To validate this hypothesis, we conducted a comprehensive study involving the cultivation, rigorous validation, and subsequent treatment of ameloblastoma patient-derived organoids (APDOs) with either a PD-L1 inhibitor, a PI3K-AKT-mTOR inhibitor, or a combination of both. The gene discussed is AKT1; the disease is ameloblastoma.